Testosterone addition to estrogen therapy Effects on inflammatory markers for cardiovascular disease

Gynecological Endocrinology

Volumn 25, Issue 12, 2009, Pages 823-827

  Kocoska Maras, Ljiljana ^a   Hirschberg, Angelica Lindén ^a   Byström, Birgitta ^a   Schoultz, Bo Von ^a   Rådestad, Angelique Flöter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Estrogen therapy; Homocysteine; HsCRP; IGFBP 1; IL 6; Testosterone; TNF ; VCAM 1

Indexed keywords

ANDROGEN; C REACTIVE PROTEIN; ESTRADIOL; ESTRADIOL VALERATE; HOMOCYSTEINE; INTERLEUKIN 6; PLACEBO; SEX HORMONE; SOMATOMEDIN BINDING PROTEIN 1; TESTOSTERONE UNDECANOATE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADD ON THERAPY; ADULT; ANDROGEN THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; INFLAMMATION; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BODY WEIGHT; C-REACTIVE PROTEIN; CHEMILUMINESCENT MEASUREMENTS; CROSS-OVER STUDIES; DIHYDROTESTOSTERONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HOMOCYSTEINE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INTERLEUKIN-6; LUTEINIZING HORMONE; MIDDLE AGED; PATIENT SELECTION; POSTMENOPAUSE; RADIOIMMUNOASSAY; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 70450212206     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903056134     Document Type: Article

References (32)

1. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
2. Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol 2008;51:564-580.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
4. Libby P, Ridker PM. Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med 2004;116 (Suppl 6A):9S-16S.
5. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-2599.
6. Schram MT, Stehouwer CD. Endothelial dysfunction, cellular adhesion molecules and the metabolic syndrome. Horm Metab Res 2005;37 (Suppl 1):49-55.
7. Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 2008;79(8 Suppl):1544-1551.
8. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006;53:252-259. (Pubitemid 43163060)
9. Friso S, Lamon-Fava S, Jang H, Schaefer EJ, Coorocher R, Choi SW. Oestrogen replacement therapy reduces total plasma homocysteine and enhances genomic DNA methylation in postmenopausal women. Br J Nutr 2007;97:617-621.
10. Arlt W. Androgen therapy in women. Eur J Endocrinol 2006;154:1-11.
11. Bell RJ, Davison SL, Papalia, MA, McKenzie DP, Davis BA, Susan R. Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause 2007;14:630-638.
12. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217.
13. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005;(4):CD004509.
14. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Androgen therapy in women: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:3697-3710.
15. Maturana MA, Breda V, Lhullier F, Spritzer PM. Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. Metabolism 2008;57:961-965.
16. Khatibi A, Agardh CD, Shakir YA, Nerbrand C, Nyberg P, Lidfeldt J, Samsioe G. Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women's Health in the Lund Area (WHILA) Study. Climacteric 2007;10:386-392. (Pubitemid 47402940)
17. Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996;24:1-19.
18. Winkler UH. Effects of androgens on haemostasis. Maturitas 1996;24:147-155.
19. Floter A, Nathorst-Boos J, Carlstrom K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: Effects on sexuality and well-being. Climacteric 2002;5:357-365.
20. Floter A, Nathorst-Boos J, Carlstrom K, von Schoultz B. Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy. Maturitas 2004;47:123-129.
21. Floter A, Nathorst-Boos J, Carlstrom K, Ohlsson C, Ringertz H, Schoultz B. Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women. Gynecol Endocrinol 2005;20:155-160.
22. Brody S, Carlstrom K, Lagrelius A, Lunell NO, Rosenborg L. Serum levels of 4-androstene-3,17-dione in menstruating and postmenopausal women. Evaluation of a radioimmunoassay and correlation with bone mineral content and endometrial pathology. Acta Obstet Gynecol Scand 1983;62:531-534.
23. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-810.
24. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care professionals from the CRP Pooling Project members. Stroke 2005;36:1316-1329.
25. Ridker PM. The time for cardiovascular inflammation reduction trials has arrived: how low to go for? Arterioscler Thromb Vasc Biol 2008;28:1222-1224.
26. Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005;52:111-118.
27. Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008;93:1702-1710.
28. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest 2001;107:1209-1210.
29. Mueck A, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: Transdermal versus oral application. Menopause 2007;14:978-984.
30. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: Relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 1998;18:277-282.
31. Mozzanega B, Babbo GL, Salmaso L, De Toni R, Schiavo A, Mioni R, de Kreutzenberg SV. Oral 17 beta-estradiol and sequential progesterone in menopause: Effects on insulin-like growth factors and their binding proteins. Gynecol Endocrinol 2007;23:50-57.
32. Heald A, Kaushal K, Anderson S, Redpath M, Durrington PN, Selby PL, Gibson MJ. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)- 1 to IGFBP-4: Implications for cardiovascular risk. Gynecol Endocrinol 2005;20:176-182.